Quince Therapeutics, Inc. (QNCX)

Market Cap	59.40M
Revenue (ttm)	n/a
Net Income (ttm)	-56.83M
Shares Out	44.00M
EPS (ttm)	-1.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,654
Open	1.380
Previous Close	1.400
Day's Range	1.330 - 1.410
52-Week Range	0.512 - 2.450
Beta	0.71
Analysts	Strong Buy
Price Target	8.00 (+492.59%)
Earnings Date	Mar 24, 2025

About QNCX

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: QNCX
• Website: https://www.quincetx.com

Analyst Forecast

According to 5 analysts, the average rating for QNCX stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 492.59% from the latest price.

Price Target

$8.0

(492.59% upside)

Analyst Consensus: Strong Buy